Molecular and biological aspects of forecasting the oncological efficiency of cytoreductive surgery in metastatic colon cancer

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Through an immunohistochemical study, the molecular biological properties of adenocarcinoma in patients with stage IV colorectal cancer with synchronous unresectable liver metastases, who underwent cytoreductive interventions for volume removal of the primary tumor, were examined. This study clarified the criteria for selecting patients with stage IV colon cancer with unresectable synchronous metastases in the liver for cytoreductive surgery from the standpoint of the molecular biological properties of the tumor. The prognostic significance of immunohistochemical markers such as the index of proliferative activity of stem cancer cells (ALDH + Ki-67 +) and the receptor for chemokines CXCR4 was established. The level of their expression correlates with the life expectancy of patients who underwent cytoreductive surgery. Thus, the high proliferative activity of cancer stem cells (ALDH + Ki67 + > 50%) and the high expression of chemokine receptor (CXCR4 > 70%) correlate with the rapid disease progression after surgical treatment. A significant inverse relationship was traced between the expression level of the receptor for chemokine CXCR4 as well as the proliferative activity of cancer stem cells and life expectancy of patients with stage IV colon cancer after cytoreductive surgery. The expediency of immunohistochemical studies in patients with metastatic colon cancer has been substantiated. Its implementation provides important information about the potential for tumor aggressiveness, which makes it possible to clarify the indications for performing cytoreductive surgery and improve the results of surgical treatment of this category of patients.

作者简介

Aleksey Sazonov

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

编辑信件的主要联系方式.
Email: sazonov_alex_doc@mail.ru
ORCID iD: 0000-0003-4726-7557
SPIN 代码: 4042-7710

doctor of medical sciences

俄罗斯联邦, Saint Petersburg

Nicolay Maistrenko

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: nik.m.47@mail.ru
ORCID iD: 0000-0002-1405-7660
SPIN 代码: 2571-9603

doctor of medical sciences, professor

俄罗斯联邦, Saint Petersburg

Pavel Romashchenko

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: omashchenko@rambler.ru
ORCID iD: 0000-0001-8918-1730
SPIN 代码: 3850-1792

doctor of medical sciences, professor

俄罗斯联邦, Saint Petersburg

参考

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
  2. Kaprin AD, Starinskij AD, Petrova GV. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2017 godu. Moscow: MNIOI PA. Gercena filial FGBU «NMIRC» Minzdrava Rossii; 2018. 236 p. (In Russ.).
  3. Afanas’ev SG, Dobrodeev AYU. Citoreduktivnye operacii (Nuzhno li udalyat’ pervichnuyu opuhol’? Gde predel razumnoj citoredukcii?). Practical Oncology. 2014;15(2):93–100. (In Russ.).
  4. Hrykov GN, Strukov EYu, Romashchenko PN, et al. Rannyaya reabilitaciya posle hirurgicheskogo lecheniya raka obodochnoj kishki u bol’nyh pozhilogo i starcheskogo vozrasta. Bulletin of the Russian Military Medical Academy. 2014;(2):400. (In Russ.).
  5. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34(4): 797–807. doi: 10.1007/s00268-009-0366-y
  6. Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumors in patients with stage IV colorectal cancers. Int J Surg. 2010;8(4):305–313. doi: 10.1016/j.ijsu.2010.03.005
  7. Ferrand F, Malka D, Bourredjem A. Impact of primary tumor resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy. Eur J Cancer. 2013;49(1):90–97. doi: 10.1016/j.ejca.2012.07.006
  8. Wang X, Mao M, Xu G. The incidence, associated factors and predictive nomogram for early death in stage IV colorectal cancer. International Journal of Colorectal Disease. 2019;34(7):1189–1201. doi: 10.1007/s00384-019-03306-1
  9. Raskin GA. Kliniko-morfologicheskaya ocenka prognosticheskih i prediktivnyh faktorov pri adenokarcinome tolstoj kishki: Dis. … d-ra. med. nauk. Saint Petersburg; 2015. 238 p. (In Russ.). Available from: https://search.rsl.ru/ru/record/01005557331
  10. Manihas GM, Majstrenko NA, Sazonov AA. influence of the age factor and tumor immunophenotype on the effectiveness of cytoreductive operations in metastatic colorectal cancer. Problems in Oncology. 2019;65(6):855–862. (In Russ.).
  11. Perfil’eva YV, Abdolla NN, Kustova EA. Ekspressiya markerov adgezii CD62L, CD44 i CXCR4 na NK-kletkah pri onkologicheskih zabolevaniyah. Cytokines and Inflammation. 2012;11(1):86–90. (In Russ.).
  12. Xu X, Pan Y, Feng Z. Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts. Br J of Cancer. 2019;120(10):987–995. doi: 10.1038/s41416-019-0450-5

补充文件

附件文件
动作
1. JATS XML

版权所有 © Sazonov A.A., Maistrenko N.A., Romashchenko P.N., 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

##common.cookie##